Overcoming T cell exhaustion in infection and cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
Zajac, 1998, Viral immune evasion due to persistence of activated T cells without effector function, J. Exp. Med., 188, 2205, 10.1084/jem.188.12.2205
Gallimore, 1998, Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes, J. Exp. Med., 187, 1383, 10.1084/jem.187.9.1383
Goepfert, 2000, A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon, J. Virol., 74, 10249, 10.1128/JVI.74.21.10249-10255.2000
Kostense, 2001, High viral burden in the presence of major HIV-specific CD8(+) T cell expansions: evidence for impaired CTL effector function, Eur. J. Immunol., 31, 677, 10.1002/1521-4141(200103)31:3<677::AID-IMMU677>3.0.CO;2-M
Shankar, 2000, Impaired function of circulating HIV-specific CD8(+) T cells in chronic human immunodeficiency virus infection, Blood, 96, 3094, 10.1182/blood.V96.9.3094
Gruener, 2001, Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus, J. Virol., 75, 5550, 10.1128/JVI.75.12.5550-5558.2001
Lechner, 2000, Analysis of successful immune responses in persons infected with hepatitis C virus, J. Exp. Med., 191, 1499, 10.1084/jem.191.9.1499
Reignat, 2002, Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection, J. Exp. Med., 195, 1089, 10.1084/jem.20011723
Lee, 1999, Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients, Nat. Med., 5, 677, 10.1038/9525
Barber, 2006, Restoring function in exhausted CD8 T cells during chronic viral infection, Nature, 439, 682, 10.1038/nature04444
Iwai, 2002, Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade, Proc. Natl. Acad. Sci. U.S.A., 99, 12293, 10.1073/pnas.192461099
Hirano, 2005, Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity, Cancer Res., 65, 1089, 10.1158/0008-5472.1089.65.3
Sharma, 2011, Novel cancer immunotherapy agents with survival benefit: recent successes and next steps, Nat. Rev. Cancer, 11, 805, 10.1038/nrc3153
Page, 2014, Immune modulation in cancer with antibodies, Annu. Rev. Med., 65, 185, 10.1146/annurev-med-092012-112807
Schreiber, 2011, Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion, Science, 331, 1565, 10.1126/science.1203486
Schietinger, 2014, Tolerance and exhaustion: defining mechanisms of T cell dysfunction, Trends Immunol., 35, 51, 10.1016/j.it.2013.10.001
Kim, 2010, Features of responding T cells in cancer and chronic infection, Curr. Opin. Immunol., 22, 223, 10.1016/j.coi.2010.02.005
Callahan, 2013, At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy, J. Leukoc. Biol., 94, 41, 10.1189/jlb.1212631
Hamid, 2013, Safety and tumor responses with lambrolizumab (Anti-PD-1) in melanoma, N. Engl. J. Med., 369, 134, 10.1056/NEJMoa1305133
Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N. Engl. J. Med., 366, 2443, 10.1056/NEJMoa1200690
Brahmer, 2010, Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates, J. Clin. Oncol., 28, 3167, 10.1200/JCO.2009.26.7609
Ohaegbulam, 2015, Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway, Trends Mol. Med., 21, 24, 10.1016/j.molmed.2014.10.009
Brahmer, 2012, Safety and activity of anti-PD-L1 antibody in patients with advanced cancer, N. Engl. J. Med., 366, 2455, 10.1056/NEJMoa1200694
Lipson, 2013, Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody, Clin. Cancer Res., 19, 462, 10.1158/1078-0432.CCR-12-2625
Wolchok, 2013, Nivolumab plus ipilimumab in advanced melanoma, N. Engl. J. Med., 369, 122, 10.1056/NEJMoa1302369
Herbst, 2014, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, 515, 563, 10.1038/nature14011
Powles, 2014, MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer, Nature, 515, 558, 10.1038/nature13904
Topalian, 2014, Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab, J. Clin. Oncol., 32, 1020, 10.1200/JCO.2013.53.0105
Robert, 2015, Nivolumab in previously untreated melanoma without BRAF mutation, N. Engl. J. Med., 372, 320, 10.1056/NEJMoa1412082
Ansell, 2015, PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma, N. Engl. J. Med., 372, 311, 10.1056/NEJMoa1411087
Wherry, 2007, Molecular signature of CD8+ T cell exhaustion during chronic viral infection, Immunity, 27, 670, 10.1016/j.immuni.2007.09.006
Blackburn, 2009, Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection, Nat. Immunol., 10, 29, 10.1038/ni.1679
Paley, 2012, Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection, Science, 338, 1220, 10.1126/science.1229620
Johnston, 2014, The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function, Cancer Cell, 26, 923, 10.1016/j.ccell.2014.10.018
Keir, 2008, PD-1 and its ligands in tolerance and immunity, Annu. Rev. Immunol., 26, 677, 10.1146/annurev.immunol.26.021607.090331
Fife, 2011, The role of the PD-1 pathway in autoimmunity and peripheral tolerance, Ann. N. Y. Acad. Sci., 1217, 45, 10.1111/j.1749-6632.2010.05919.x
Pauken, 2013, PD-1, but not PD-L1, expressed by islet-reactive CD4+ T cells suppresses infiltration of the pancreas during type 1 diabetes, Diabetes, 62, 2859, 10.2337/db12-1475
Schietinger, 2012, Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state, Science, 335, 723, 10.1126/science.1214277
Duraiswamy, 2011, Phenotype, function, and gene expression profiles of programmed death-1(hi) CD8 T cells in healthy human adults, J. Immunol., 186, 4200, 10.4049/jimmunol.1001783
Wherry, 2003, Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment, J. Virol., 77, 4911, 10.1128/JVI.77.8.4911-4927.2003
Jin, 1999, Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques, J. Exp. Med., 189, 991, 10.1084/jem.189.6.991
Schmitz, 1999, Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes, Science, 283, 857, 10.1126/science.283.5403.857
Blattman, 2009, Impact of epitope escape on PD-1 expression and CD8 T-cell exhaustion during chronic infection, J. Virol., 83, 4386, 10.1128/JVI.02524-08
Jamieson, 2003, Epitope escape mutation and decay of human immunodeficiency virus type 1-specific CTL responses, J. Immunol., 171, 5372, 10.4049/jimmunol.171.10.5372
Prakash, 2014, Granzyme B promotes cytotoxic lymphocyte transmigration via basement membrane remodeling, Immunity, 41, 960, 10.1016/j.immuni.2014.11.012
Surh, 2008, Homeostasis of naive and memory T cells, Immunity, 29, 848, 10.1016/j.immuni.2008.11.002
Wherry, 2004, Antigen-independent memory CD8 T cells do not develop during chronic viral infection, Proc. Natl. Acad. Sci. U.S.A., 101, 16004, 10.1073/pnas.0407192101
Shin, 2007, Viral antigen and extensive division maintain virus-specific CD8 T cells during chronic infection, J. Exp. Med., 204, 941, 10.1084/jem.20061937
Obar, 2006, Gammaherpesvirus persistence alters key CD8 T-cell memory characteristics and enhances antiviral protection, J. Virol., 80, 8303, 10.1128/JVI.00237-06
Alter, 2003, Longitudinal assessment of changes in HIV-specific effector activity in HIV-infected patients starting highly active antiretroviral therapy in primary infection, J. Immunol., 171, 477, 10.4049/jimmunol.171.1.477
Oxenius, 2002, Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection, Proc. Natl. Acad. Sci. U.S.A., 99, 13747, 10.1073/pnas.202372199
Utzschneider, 2013, T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion, Nat. Immunol., 14, 603, 10.1038/ni.2606
Angelosanto, 2012, Progressive loss of memory T cell potential and commitment to exhaustion during chronic viral infection, J. Virol., 86, 8161, 10.1128/JVI.00889-12
Schwartz, 2003, T cell anergy, Annu. Rev. Immunol., 21, 305, 10.1146/annurev.immunol.21.120601.141110
Doering, 2012, Network analysis reveals centrally connected genes and pathways involved in CD8+ T cell exhaustion versus memory, Immunity, 37, 1130, 10.1016/j.immuni.2012.08.021
Crawford, 2014, Molecular and transcriptional basis of CD4(+) T cell dysfunction during chronic infection, Immunity, 40, 289, 10.1016/j.immuni.2014.01.005
Blackburn, 2008, Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade, Proc. Natl. Acad. Sci. U.S.A., 105, 15016, 10.1073/pnas.0801497105
Buggert, 2014, T-bet and Eomes are differentially linked to the exhausted phenotype of CD8+ T cells in HIV infection, PLoS Pathog., 10, e1004251, 10.1371/journal.ppat.1004251
Kaech, 2012, Transcriptional control of effector and memory CD8+ T cell differentiation, Nat. Rev. Immunol., 12, 749, 10.1038/nri3307
Paley, 2013, Technical advance: fluorescent reporter reveals insights into eomesodermin biology in cytotoxic lymphocytes, J. Leukoc. Biol., 93, 307, 10.1189/jlb.0812400
Intlekofer, 2005, Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin, Nat. Immunol., 6, 1236, 10.1038/ni1268
Zhou, 2010, Differentiation and persistence of memory CD8(+) T cells depend on T cell factor 1, Immunity, 33, 229, 10.1016/j.immuni.2010.08.002
Banerjee, 2010, Cutting edge: the transcription factor eomesodermin enables CD8+ T cells to compete for the memory cell niche, J. Immunol., 185, 4988, 10.4049/jimmunol.1002042
Intlekofer, 2007, Requirement for T-bet in the aberrant differentiation of unhelped memory CD8+ T cells, J. Exp. Med., 204, 2015, 10.1084/jem.20070841
Mullen, 2011, Master transcription factors determine cell-type-specific responses to TGF-beta signaling, Cell, 147, 565, 10.1016/j.cell.2011.08.050
Trompouki, 2011, Lineage regulators direct BMP and Wnt pathways to cell-specific programs during differentiation and regeneration, Cell, 147, 577, 10.1016/j.cell.2011.09.044
Curran, 2013, Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin, J. Exp. Med., 210, 743, 10.1084/jem.20121190
Fahey, 2011, Viral persistence redirects CD4 T cell differentiation toward T follicular helper cells, J. Exp. Med., 208, 987, 10.1084/jem.20101773
Brooks, 2005, Intrinsic functional dysregulation of CD4 T cells occurs rapidly following persistent viral infection, J. Virol., 79, 10514, 10.1128/JVI.79.16.10514-10527.2005
Fuller, 2003, Ablation of CD8 and CD4 T cell responses by high viral loads, J. Immunol., 170, 477, 10.4049/jimmunol.170.1.477
Oxenius, 1998, Comparison of activation versus induction of unresponsiveness of virus-specific CD4+ and CD8+ T cells upon acute versus persistent viral infection, Immunity, 9, 449, 10.1016/S1074-7613(00)80628-7
Matloubian, 1994, CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection, J. Virol., 68, 8056, 10.1128/JVI.68.12.8056-8063.1994
Schenkel, 2014, T cell memory. Resident memory CD8 T cells trigger protective innate and adaptive immune responses, Science, 346, 98, 10.1126/science.1254536
Curiel, 2003, Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity, Nat. Med., 9, 562, 10.1038/nm863
Fourcade, 2010, Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients, J. Exp. Med., 207, 2175, 10.1084/jem.20100637
Baitsch, 2011, Exhaustion of tumor-specific CD8(+) T cells in metastases from melanoma patients, J. Clin. Invest., 121, 2350, 10.1172/JCI46102
Riches, 2013, T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production, Blood, 121, 1612, 10.1182/blood-2012-09-457531
Gros, 2014, PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors, J. Clin. Invest., 124, 2246, 10.1172/JCI73639
Ahmadzadeh, 2009, Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired, Blood, 114, 1537, 10.1182/blood-2008-12-195792
Mumprecht, 2009, Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression, Bloiod, 114, 1528, 10.1182/blood-2008-09-179697
Fourcade, 2009, PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients, J. Immunol., 182, 5240, 10.4049/jimmunol.0803245
Radoja, 2001, CD8(+) tumor-infiltrating T cells are deficient in perforin-mediated cytolytic activity due to defective microtubule-organizing center mobilization and lytic granule exocytosis, J. Immunol., 167, 5042, 10.4049/jimmunol.167.9.5042
Matsuzaki, 2010, Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer, Proc. Natl. Acad. Sci. U.S.A., 107, 7875, 10.1073/pnas.1003345107
Sfanos, 2009, Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+, Prostate, 69, 1694, 10.1002/pros.21020
Muenst, 2013, The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer, Breast Cancer Res. Treat., 139, 667, 10.1007/s10549-013-2581-3
Zhang, 2010, Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer, Cell. Mol. Immunol., 7, 389, 10.1038/cmi.2010.28
Spranger, 2013, Up-regulation of PD–L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells, Sci. Transl. Med., 5, 200ra116, 10.1126/scitranslmed.3006504
Tumeh, 2014, PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, 515, 568, 10.1038/nature13954
Savage, 2014, Shaping the repertoire of tumor-infiltrating effector and regulatory T cells, Immunol. Rev., 259, 245, 10.1111/imr.12166
Jin, 2010, Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection, Proc. Natl. Acad. Sci. U.S.A., 107, 14733, 10.1073/pnas.1009731107
McMahan, 2010, Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity, J. Clin. Invest., 120, 4546, 10.1172/JCI43127
Nakamoto, 2009, Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade, PLoS Pathog., 5, e1000313, 10.1371/journal.ppat.1000313
Topalian, 2012, Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity, Curr. Opin. Immunol., 24, 207, 10.1016/j.coi.2011.12.009
Wilson, 2013, Blockade of chronic type I interferon signaling to control persistent LCMV infection, Science, 340, 202, 10.1126/science.1235208
Teijaro, 2013, Persistent LCMV infection is controlled by blockade of type I interferon signaling, Science, 340, 207, 10.1126/science.1235214
Yi, 2009, A vital role for interleukin-21 in the control of a chronic viral infection, Science, 324, 1572, 10.1126/science.1175194
Frohlich, 2009, IL-21R on T cells is critical for sustained functionality and control of chronic viral infection, Science, 324, 1576, 10.1126/science.1172815
Elsaesser, 2009, IL-21 is required to control chronic viral infection, Science, 324, 1569, 10.1126/science.1174182
Brooks, 2006, Interleukin-10 determines viral clearance or persistence in vivo, Nat. Med., 12, 1301, 10.1038/nm1492
Kao, 2011, Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection, Nat. Immunol., 12, 663, 10.1038/ni.2046
Staron, 2014, The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection, Immunity, 41, 802, 10.1016/j.immuni.2014.10.013
Shin, 2009, A role for the transcriptional repressor Blimp-1 in CD8(+) T cell exhaustion during chronic viral infection, Immunity, 31, 309, 10.1016/j.immuni.2009.06.019
Oestreich, 2008, NFATc1 regulates PD-1 expression upon T cell activation, J. Immunol., 181, 4832, 10.4049/jimmunol.181.7.4832
Yokosuka, 2012, Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2, J. Exp. Med., 209, 1201, 10.1084/jem.20112741
Chemnitz, 2004, SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation, J. Immunol., 173, 945, 10.4049/jimmunol.173.2.945
Riley, 2009, PD-1 signaling in primary T cells, Immunol. Rev., 229, 114, 10.1111/j.1600-065X.2009.00767.x
Sheppard, 2004, PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta, FEBS Lett., 574, 37, 10.1016/j.febslet.2004.07.083
Parry, 2005, CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms, Mol. Cell. Biol., 25, 9543, 10.1128/MCB.25.21.9543-9553.2005
Patsoukis, 2012, Selective effects of PD–1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation, Sci. Signal., 5, ra46, 10.1126/scisignal.2002796
Quigley, 2010, Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF, Nat. Med., 16, 1147, 10.1038/nm.2232
Fife, 2009, Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal, Nat. Immunol., 10, 1185, 10.1038/ni.1790
Honda, 2014, Tuning of antigen sensitivity by T cell receptor-dependent negative feedback controls T cell effector function in inflamed tissues, Immunity, 40, 235, 10.1016/j.immuni.2013.11.017
Zinselmeyer, 2013, PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis, J. Exp. Med., 210, 757, 10.1084/jem.20121416
Iwai, 2005, PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells, Int. Immunol., 17, 133, 10.1093/intimm/dxh194
Strome, 2003, B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma, Cancer Res., 63, 6501
Blank, 2004, PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells, Cancer Res., 64, 1140, 10.1158/0008-5472.CAN-03-3259
Gubin, 2014, Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens, Nature, 515, 577, 10.1038/nature13988
Twyman-Saint Victor, 2015, Radiation and dual checkpoint blockade activate non–redundant immune mechanisms in cancer, Nature, 10.1038/nature14292
Mueller, 2010, PD-L1 has distinct functions in hematopoietic and nonhematopoietic cells in regulating T cell responses during chronic infection in mice, J. Clin. Invest., 120, 2508, 10.1172/JCI40040
Yadav, 2014, Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing, Nature, 515, 572, 10.1038/nature14001
Peng, 2012, PD-1 blockade enhances T-cell migration to tumors by elevating IFN-gamma inducible chemokines, Cancer Res., 72, 5209, 10.1158/0008-5472.CAN-12-1187
Pilon-Thomas, 2010, Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma, J. Immunol., 184, 3442, 10.4049/jimmunol.0904114
Yang, 2015, Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: a review, Crit. Rev. Oncol. Hematol., 93, 277, 10.1016/j.critrevonc.2014.11.001
Xiao, 2014, RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance, J. Exp. Med., 211, 943, 10.1084/jem.20130790
Martinez, 2015, The transcription factor NFAT promotes exhaustion of activated CD8 T cells, Immunity, 42, 265, 10.1016/j.immuni.2015.01.006
Pollizzi, 2014, Integrating canonical and metabolic signalling programmes in the regulation of T cell responses, Nat. Rev. Immunol., 14, 435, 10.1038/nri3701
Lu, 2014, Blimp-1 represses CD8 T cell expression of PD-1 using a feed-forward transcriptional circuit during acute viral infection, J. Exp. Med., 211, 515, 10.1084/jem.20130208
Youngblood, 2011, Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells, Immunity, 35, 400, 10.1016/j.immuni.2011.06.015
Youngblood, 2013, Cutting edge: Prolonged exposure to HIV reinforces a poised epigenetic program for PD-1 expression in virus-specific CD8 T cells, J. Immunol., 191, 540, 10.4049/jimmunol.1203161